Multiple sclerosis severity score -: Using disability and disease duration to rate disease severity
Multiple sclerosis severity score -: Using disability and disease duration to rate disease severity
复制标题
DOI：
10.1212/01.wnl.0000156155.19270.f8
复制
发表时间：
2005-04-12
期刊：
影响因子：
9.9
通讯作者：
Compston, DAS
中科院分区：
文献类型：
--
作者：
Roxburgh, RHSR;Seaman, SR;Compston, DAS
背景：当每位患者在病程中仅进行过一次评估时，没有一致的方法来确定多发性硬化症（MS）患者的残疾进展。方法：作者利用两个大型纵向数据库的数据，测试了横截面残疾评估是否能代表整个疾病的严重程度。设计了一种算法，即多发性硬化症严重程度评分 (MSSS)，它将扩展残疾状态量表 (EDSS) 的评分与具有可比病程的患者的残疾分布联系起来，然后应用于来自 11 个国家的 9,892 名患者，以创建全球 MSSS。为了比较检测此类影响的不同方法，作者模拟了遗传因素对残疾的影响。结果：第一年后进行的横截面 EDSS 测量代表了总体疾病严重程度。 MSSS 比作者测试的其他检测不同疾病进展率的方法更强大。结论：多发性硬化症严重程度评分 (MSSS) 是使用单一评估数据比较疾病进展的有效方法。全球 MSSS 可作为未来残疾比较的参考表。虽然对于比较患者群体很有用，但疾病波动使其无法用作个体未来残疾的预测指标。
Background: There is no consensus method for determining progression of disability in patients with multiple sclerosis (MS) when each patient has had only a single assessment in the course of the disease. Methods: Using data from two large longitudinal databases, the authors tested whether cross-sectional disability assessments are representative of disease severity as a whole. An algorithm, the Multiple Sclerosis Severity Score (MSSS), which relates scores on the Expanded Disability Status Scale (EDSS) to the distribution of disability in patients with comparable disease durations, was devised and then applied to a collection of 9,892 patients from 11 countries to create the Global MSSS. In order to compare different methods of detecting such effects the authors simulated the effects of a genetic factor on disability. Results: Cross-sectional EDSS measurements made after the first year were representative of overall disease severity. The MSSS was more powerful than the other methods the authors tested for detecting different rates of disease progression. Conclusion: The Multiple Sclerosis Severity Score (MSSS) is a powerful method for comparing disease progression using single assessment data. The Global MSSS can be used as a reference table for future disability comparisons. While useful for comparing groups of patients, disease fluctuation precludes its use as a predictor of future disability in an individual.